10-K: EyePoint's DURAVYU Advances to Phase 3 Amidst Rising Losses

EyePoint, Inc. reports a net loss of $232.0 million for fiscal year 2025, driven by increased R&D for its lead candidate DURAVYU, which is progressing in Phase 3 trials for wet AMD and DME.

Summary

• EyePoint, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for serious retinal diseases, leveraging its proprietary bioerodible Durasert E technology.
• The lead product candidate, DURAVYU, an investigational sustained delivery treatment combining vorolanib (a tyrosine kinase inhibitor) with Durasert E, is in Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
• Enrollment for the Phase 3 wet AMD trials (LUGANO and LUCIA) is complete, with data anticipated beginning in mid-2026.
• The first patient was dosed in the Phase 3 DME program (COMO and CAPRI) in February 2026, following positive Phase 2 VERONA trial results.
• The company reported a net loss of $231.962 million for the year ended December 31, 2025, a significant increase from $130.870 million in 2024.
• Total revenues decreased by 28% to $31.371 million in 2025, primarily due to the termination of a commercial supply agreement and reduced license/collaboration revenues.
• Research and development expenses increased by 66% to $221.039 million in 2025, reflecting substantial investment in DURAVYU's clinical development and manufacturing scale-up.
• Cash, cash equivalents, and investments in marketable securities totaled $306.1 million at December 31, 2025, projected to fund operations into the fourth quarter of 2027.
• An agreement in principle was reached in the first quarter of 2026 with the U.S. Department of Justice (DOJ) and the Office of the Inspector General of the Department of Health and Human Services (HHS) to settle an investigation into sales, marketing, and promotional practices related to DEXYCU for approximately $4.7 million plus interest, including a corporate integrity agreement.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral-to-slightly-negative report. While significant clinical progress for DURAVYU is positive, the substantial increase in net loss and decrease in revenue, coupled with ongoing capital needs and regulatory challenges, present financial headwinds.

Positives

• DURAVYU's Phase 3 wet AMD trials (LUGANO and LUCIA) have completed enrollment, with topline data expected in mid-2026, marking significant progress for the lead candidate.
• The Phase 3 DME program (COMO and CAPRI) for DURAVYU has initiated patient dosing, building on successful Phase 2 VERONA trial outcomes.
• The Phase 2 VERONA trial for DME met both primary and secondary endpoints, demonstrating meaningful and sustained improvements in visual acuity (+7.1 letters BCVA gain) and anatomical control (76-micron CST reduction) with a favorable safety profile.
• Preclinical data identified vorolanib (DURAVYU's active agent) as a multi-mechanism therapy, inhibiting VEGF receptors, PDGF, and pro-inflammatory IL-6/JAK1 signaling, which differentiates it from existing anti-VEGF treatments.
• The Durasert E drug delivery technology has a proven safety record, having been safely administered in thousands of patient eyes across four FDA-approved products.
• The company completed the grand opening of its new cGMP-compliant commercial manufacturing facility in Northbridge, MA, designed to support global manufacturing, including DURAVYU upon potential regulatory approval.
• Cash, cash equivalents, and marketable securities of $306.1 million at December 31, 2025, are expected to fund operations into Q4 2027, extending beyond the anticipated Phase 3 wet AMD topline data readout.
• An agreement in principle was reached with the DOJ and HHS to settle the DEXYCU investigation for approximately $4.7 million plus interest, potentially avoiding prolonged litigation and larger penalties.

Negatives

• The company incurred a net loss of $231.962 million in 2025, a 77% increase from $130.870 million in 2024, indicating a worsening financial performance.
• The accumulated deficit reached $1,105.0 million at December 31, 2025, highlighting a history of significant operating losses.
• Total revenues decreased by 28% to $31.371 million in 2025 from $43.273 million in 2024, primarily due to the termination of the ANI commercial supply agreement.
• Product sales, net, decreased by 50% to $1.6 million in 2025 compared to $3.2 million in 2024.
• Interest and other income, net, decreased by 22% to $11.784 million in 2025, attributed to lower market interest rates and reduced cash available for investment.
• Research and development expenses increased substantially by 66% to $221.039 million in 2025, contributing to the increased net loss.
• The company will likely require additional capital to fund operations beyond the fourth quarter of 2027, with no assurance of availability on favorable terms, posing a risk of dilution to existing stockholders.
• A Warning Letter was received from the FDA in July 2024 regarding YUTIQ manufacturing at the Watertown facility, citing cGMP violations, which required the implementation of corrective and preventive actions.

Risks

• The company will likely need additional capital to fund operations, and if unable to obtain sufficient capital, it will need to curtail operations and modify its business strategy.
• Significant losses have been incurred since inception, and the company anticipates continuing losses for the foreseeable future, with no guarantee of achieving profitability.
• The finalization of the negotiated resolution with the U.S. government regarding the DOJ investigation is not guaranteed, and non-compliance with any resulting corporate integrity agreement could lead to substantial penalties or exclusion from federal healthcare programs.
• Future capital raises may not be available on favorable terms and could be dilutive to stockholders or impose operational restrictions.
• The company's ability to use its net operating loss carryforwards and other tax attributes may be limited by Section 382 of the Internal Revenue Code.
• The business is substantially dependent on the success of its lead product candidate, DURAVYU; failure in clinical development, regulatory approval, or commercialization would significantly harm the business.
• Clinical trial outcomes are uncertain, and delays or termination of trials for DURAVYU or other product candidates could harm the business, financial condition, and prospects.
• Disruptions at the FDA, including workforce reductions or inadequate funding, could delay regulatory processes and negatively impact the business.
• Interim, top-line, initial, and preliminary data from clinical trials may change as more patient data become available, potentially leading to different conclusions.
• Expending significant resources on DURAVYU for wet AMD and DME may lead to missed opportunities for other potentially more profitable indications.
• Phase 1 or 2 clinical trial results do not guarantee success in later-stage trials, and systemic toxicities previously observed with oral vorolanib could recur.
• Difficulty enrolling patients in clinical trials could delay or prevent the completion of trials.
• Product candidates, if approved, may not achieve market acceptance or be commercially successful due to factors like efficacy, safety, cost, reimbursement, and competition.
• Unfavorable pricing regulations, third-party reimbursement practices, or healthcare reform initiatives (e.g., Affordable Care Act, Inflation Reduction Act, OBBBA) could harm the business and limit revenues.
• Failure to comply with reporting and payment obligations under government pricing programs (Medicaid Drug Rebate, 340B, Medicare Part B/D, VA FSS) could result in additional reimbursement requirements, penalties, and fines.
• Even after regulatory approval, products like DEXYCU face extensive FDA regulatory requirements and potential future difficulties, including costly post-approval studies (e.g., DEXYCU pediatric study).
• Relationships with physicians, patients, and payors are subject to anti-kickback, fraud, and abuse laws, and non-compliance could lead to criminal, civil, and administrative sanctions.
• If market opportunities for product candidates are smaller than believed, results of operations may be adversely affected.
• Newly discovered or developed safety problems with any product candidates could seriously harm the business.
• Patient assistance programs are under increasing scrutiny, potentially leading to harm or penalties.
• Inability to protect intellectual property rights or inadequate protection could allow competitors to commercialize similar products, harming the competitive position.
• Involvement in lawsuits to protect or enforce patents could be expensive, time-consuming, and unsuccessful.
• The development and commercialization of DURAVYU are dependent on intellectual property licensed from Equinox Science and API supply from a sole supplier; breach or termination of these agreements could be material.
• Dependence on Contract Research Organizations (CROs), Contract Manufacturing Organizations (CMOs), and other third parties for development efforts carries risks of delays or inadequate performance.
• Manufacturing operations depend on the Watertown, MA, and Northbridge, MA, facilities; destruction or inoperability of either location could adversely impact the business.
• The trading price of the company's common stock has been highly volatile, and purchasers could incur substantial losses.
• A small concentration of approximately ten stockholders beneficially own 62% of the total outstanding common stock, giving them significant control over matters subject to stockholder approval.
• Substantial future sales or other issuances of common stock could depress the market price and dilute existing stockholders.
• Provisions in charter documents (e.g., blank check preferred stock, board vacancies, advance notice for proposals, no cumulative voting, special meeting call restrictions) could prevent or delay takeover attempts.
• Computer system failures, cyberattacks, or deficiencies in cybersecurity could result in compromise of confidential information, regulatory actions, litigation, and operational disruptions.
• Failure to comply with data protection laws and regulations could lead to government enforcement actions, civil or criminal penalties, and private litigation.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for the foreseeable future, primarily due to ongoing investments in clinical trials and research and development. Cash, cash equivalents, and marketable securities are projected to fund operations into the fourth quarter of 2027, extending beyond the anticipated topline Phase 3 data for DURAVYU in wet AMD in 2026. The company plans to file a New Drug Application (NDA) for wet AMD if Phase 3 trials are successful, followed by a supplemental NDA for Year 2 safety data. Strategic goals include preparing for the potential commercial launch of DURAVYU in the U.S., advancing DURAVYU into additional retinal disease indications, progressing EYP-2301 into clinical development, and expanding the product pipeline through internal discovery, collaborations, or acquisitions. The company also anticipates submitting a final response to the FDA regarding YUTIQ manufacturing corrective actions in the first half of 2026 and finalizing the DOJ/HHS settlement in the same period.

Management Comments

• DURAVYU is on track to be the first-to-market of the current investigational sustained release treatments for wet AMD.
• DURAVYU has two potential blockbuster indications.
• DURAVYU's potential real-world application in multiple retinal disease indications and de-risked trial designs position DURAVYU for clinical and commercial success.
• Our cash, cash equivalents, and investments in marketable securities of $306.1 million at December 31, 2025 will enable us to fund operations into the fourth quarter of 2027, beyond Phase 3 wet AMD topline data for DURAVYU expected in 2026.
• We anticipate final response confirming completion of all corrective actions to be submitted during the first half of 2026 (regarding the FDA Warning Letter for YUTIQ manufacturing).
• Based on current information, we believe our other products in development, including DURAVYU, are not impacted by this regulatory action (regarding the FDA Warning Letter).

Industry Context

StockSavvy.ai notes that EyePoint operates in a highly competitive biopharmaceutical market for eye diseases, characterized by extensive research and development and rapid technological progress. The company's focus on sustained intraocular drug delivery with its Durasert E technology positions it against established anti-VEGF therapies like Lucentis, Eylea, Vabysmo, and Avastin, as well as emerging gene therapies from competitors such as REGENXBIO, Adverum Biotechnologies, 4D Molecular Therapeutics, Merck (EyeBio), and Ollin Biosciences. The multi-mechanism of action of DURAVYU (VEGF, PDGF, and IL-6/JAK1 inhibition) aims to address unmet needs in treatment duration and comprehensive disease pathogenesis beyond single-target anti-VEGF treatments, potentially offering a differentiated profile in the wet AMD and DME markets. The industry is also seeing new sustained-release technologies like Ocular Therapeutix's AXPAXLI and Kodiak Sciences' tarcocimab tedromer, indicating a strong competitive landscape for long-acting treatments.

Comparison to Industry Standards

• **DURAVYU vs. Current Anti-VEGFs (Lucentis, Eylea, Vabysmo, Beovu, Avastin):** Current treatments require frequent injections (monthly, bi-monthly, or every 3-4 months), leading to high treatment burden and reduced compliance. DURAVYU aims for a six-month sustained delivery, potentially offering a significant advantage in reducing injection frequency and improving patient compliance.
• **DURAVYU vs. SUSVIMO (ranibizumab):** SUSVIMO, a port delivery system, was approved for wet AMD in 2021 and DME in 2025, but requires initial surgical placement. DURAVYU is delivered via a standard intravitreal injection, which is similar to current anti-VEGF treatments, potentially offering a less invasive sustained-release option.
• **DURAVYU vs. AXPAXLI (Ocular Therapeutix):** AXPAXLI (axitinib, a TKI in hydrogel) is also a TKI-based sustained delivery treatment. Ocular Therapeutix reported positive Phase 3 SOL-1 superiority data for AXPAXLI in treatment-naive wet AMD and is conducting SOL-R (non-inferiority, repeat injections every six months vs. aflibercept every eight weeks). DURAVYU's multi-MOA (VEGF, PDGF, IL-6/JAK1) could differentiate it from AXPAXLI's TKI mechanism by addressing broader disease pathways.
• **DURAVYU vs. Tarcocimab Tedromer (Kodiak Sciences):** Kodiak's Phase 3 GLEAM and GLIMMER studies in DME did not meet primary efficacy endpoints, while its DAYLIGHT study in wet AMD met its primary endpoint with monthly dosing. Kodiak is also developing KSI-501 (bi-specific anti-IL-6 and VEGF trap). DURAVYU's sustained delivery and multi-MOA could offer advantages, especially given Kodiak's DME trial setbacks.
• **DURAVYU vs. Gene Therapies (REGENXBIO, Adverum, 4D Molecular Therapeutics, Merck (EyeBio), Ollin Biosciences):** These investigational treatments aim for long-term or permanent solutions but are in earlier stages (Phase 2/3 enrollment) and involve gene therapy, which has different risk/benefit profiles, regulatory pathways, and potentially higher upfront costs compared to drug inserts.

Management Changes

Corporate Governance

Legal Proceedings

• The company was subject to a U.S. Department of Justice (DOJ) investigation into sales, marketing, and promotional practices related to DEXYCU from 2019 to 2023, stemming from a sealed qui tam complaint.
• In the first quarter of 2026, an agreement in principle was reached with the DOJ to settle these matters for a payment of approximately $4.7 million plus interest (exclusive of approximately $0.2 million for relators' attorneys fees).
• On February 26, 2026, an agreement in principle was reached with the Office of the Inspector General of the Department of Health and Human Services (HHS) to resolve matters related to the DOJ investigation, which includes the company entering into a corporate integrity agreement and HHS agreeing not to seek exclusion from federal healthcare programs.
• A litigation contingency liability of approximately $4.7 million was recorded in the consolidated balance sheets as of December 31, 2025, based on the status of settlement discussions.

Related Party Transactions

• Nancy S. Lurker, former Chief Executive Officer and current Vice Chair of the Board, is a member of the board of directors of Altasciences, the parent company of Calvert Laboratories, Inc., an entity with which the company conducts business.
• The company recorded $0.9 million of research and development expense in 2025 (compared to $1.5 million in 2024) related to preclinical and analytical services provided by Altasciences.
• As of December 31, 2025, there were no accounts payable to Altasciences (compared to $0.4 million in 2024), and prepaid expenses of $0.3 million (compared to $0.2 million in 2024) related to services from Altasciences.

Stakeholder Impact

• **Shareholders:** Face potential dilution from future capital raises and continued stock price volatility. The long-term value creation hinges on DURAVYU's successful clinical development and commercialization. A significant concentration of ownership (62% by ~10 stockholders) could limit the influence of new investors.
• **Employees:** Benefit from continued investment in professional development, competitive compensation, and health/wellness programs. Equity awards and recent employment agreement amendments for executives aim to enhance retention and align interests. The company's growth plans suggest potential for career advancement.
• **Customers (future patients):** Stand to benefit from a potential new, long-acting treatment option (DURAVYU) for wet AMD and DME, which could significantly reduce the burden of frequent injections associated with current therapies.
• **Suppliers/Partners:** The company's dependence on a sole API supplier for vorolanib and its manufacturing facilities in Watertown and Northbridge creates supply chain risks. The termination of the ANI commercial supply agreement impacts revenue, while the ongoing supply agreement with Ocumension for YUTIQ continues.
• **Creditors:** The accumulated deficit and ongoing operating losses indicate a reliance on financing activities. The current cash runway into Q4 2027 provides some financial stability, but future capital needs remain a concern.

Next Steps

• Report Phase 3 wet AMD topline data for DURAVYU beginning in mid-2026.
• Continue Phase 3 global clinical trials (COMO and CAPRI) for DURAVYU in DME.
• Advance EYP-2301 into clinical development for serious retinal diseases.
• Prepare for potential commercial launch of DURAVYU in the United States.
• Advance DURAVYU into additional retinal disease indications.
• Expand product pipeline through internal discovery, research collaborations, in-licensing, or acquisition.
• Finalize settlement agreement and corporate integrity agreement with DOJ and HHS in the first half of 2026.
• Submit final response confirming completion of all corrective actions for FDA Warning Letter (YUTIQ manufacturing) in the first half of 2026.
• Complete the DEXYCU pediatric study by June 2027.

Key Dates

Recommendation

The company is making significant clinical progress with its lead candidate DURAVYU, which has shown promising Phase 2 results and is now in pivotal Phase 3 trials for two major retinal diseases. This progress, coupled with a cash runway into Q4 2027, provides a basis for optimism. However, the substantial increase in net losses, decrease in total revenues, and the ongoing need for future capital raises introduce considerable financial risk and potential for dilution. The resolution of the DOJ investigation, while positive, still incurs costs and operational burdens. A 'hold' recommendation reflects the balance between the strong clinical pipeline potential and the significant financial challenges and execution risks.

Keywords

EyePoint, EYPT, biopharmaceutical, retinal diseases, DURAVYU, wet AMD, diabetic macular edema, DME, Durasert E, vorolanib, tyrosine kinase inhibitor, TKI, clinical trials, Phase 3, FDA, SEC filing, 10-K, financial results, R&D, corporate governance, intellectual property, capital raise, NASDAQ, ophthalmology, drug delivery